AKRO Live signals | Maximize Profits with Getagraph.com

BUY 157681 min ago

@ $22.13

Issued: 14 Feb 2024 @ 14:43

Return: -14.96%

Previous signal: Feb 13 - 15:49

Previous signal: Sell

Return: 7.64 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health...

Stats
Today's Volume	680 144
Average Volume	1.15M
Market Cap	1.30B
EPS	$0 ( 2024-05-20 )
Next earnings date	( $-0.900 ) 2024-08-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.81
ATR14	$0.0320 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Young Jonathan	Sell	5 000	Common Stock
2024-04-29	Gangloff Scott A.	Buy	225 000	Stock Option (Right to Buy)
2024-04-29	Gangloff Scott A.	Buy	0
2024-04-01	Young Jonathan	Sell	4 600	Common Stock
2024-04-01	Young Jonathan	Sell	400	Common Stoek

INSIDER POWER
56.95
Last 99 transactions
Buy: 2 261 541 \| Sell: 619 470

Volume Correlation

Long: 0.57 (weak)

Short: -0.15 (neutral)

Signal:(62.088) Neutral

Akero Therapeutics Inc Correlation

10 Most Positive Correlations
OZEM	1
PRCNX	0.958
LZOEX	0.95
MACSX	0.945
MPIEX	0.943
ANTUX	0.942
MSIQX	0.937
RGSVX	0.937
MIQBX	0.937
RGIVX	0.937

10 Most Negative Correlations
AAPD	-0.903
PXMD	-0.865
HTOOW	-0.862
LDWY	-0.856
NMFCZ	-0.849
IIMFX	-0.845
PLTNU	-0.836
CLMB	-0.819
GECCI	-0.817
NWTN	-0.809

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Akero Therapeutics Inc Correlation - Currency/Commodity

-0.72
( moderate negative )

-0.63
( weak negative )

0.00
( neutral )

-0.36
( neutral )

0.39
( neutral )

Akero Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-29 000.00 (0.00 %)
EPS:	$-2.89

FY	2023
Revenue:	$0
Gross Profit:	$-29 000.00 (0.00 %)
EPS:	$-2.89

FY	2022
Revenue:	$0
Gross Profit:	$-260 000 (0.00 %)
EPS:	$-2.79

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.89

Financial Reports:

No articles found.

Akero Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Akero Therapeutics Inc

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.